Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03711318 · ClinicalTrials.gov registry record · Phase 3
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
A Phase 3 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT03711318 is a Phase 3 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants.
The verdict
NCT03711318, a Phase 3 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
A short-term treatment with buprenorphine prior to initiating treatment with naltrexone may increase the proportion of heroin-dependent patients successfully inducted onto Vivitrol.
Interventions
- DRUG Buprenorphine/naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03711318
The ClinicalTrials.gov registry entry for NCT03711318 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT03711318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03711318 about?
NCT03711318 is a clinical study titled "Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals". A short-term treatment with buprenorphine prior to initiating treatment with naltrexone may increase the proportion of heroin-dependent patients successfully inducted onto Vivitrol.
What is the current status of trial NCT03711318?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2018-11-01. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03711318?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT03711318?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.